Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA

Anneke D. van Dijk, Fieke W. Hoff, Yihua Qiu, Robert B. Gerbing, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Gaye N. Jenkins, Eveline S.J.M. de Bont, Steven M. Kornblau, Terzah M. Horton

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry